Member Info for Newuncle

Bid 32.25

But at least the Bid is now 32p

Got gouged there:

Symbol
DVRG
Quantity 21,406.00
Price £0.327

bid now 31.75p and I still haven't had my buy order from 10:54 filled!!

Order Status
Pending
Order Reference

Date
16/03/21
Time
10:54
Stock Name
DEEPVERGE PLC ORD GBP0.001
Action
Buy
Order Type
Market
Symbol
DVRG

bored waiting, banged the order in anyway, MMs and their games.

Hi Chesh,

tryin 2 bye some but can't get an order accepted for 1,000 or more....wtf are MMs playin at ere?

Hi Chesh, small (tiny really) uptick on the bid now at 30.45, I reckon soon we will be rising in 5p or 10p jumps instead though

Not long now. Just wait until the financial press get into this, will get a major re-rating imo but it's just a shame so many PIs are going to miss our on the great value to be had here right now.

In November, PulmoBioMed entered into a partnership agreement with DeepVerge plc, a company specialising in the use of artificial intelligence to detect, analyse and identify more than 2700 pathogens in clinical research, medical device, environmental and life science equipment. The partnership combines the breathalyser PBM-HALE™ with DeepVerge’s ‘MicrotoxBT’ – a micro-engineered nano-fluidic chip to detect viruses, bacteria, toxins and parasites in drinking and wastewater and identifies specific targets which includes SARS-CoV-2, within breath condensate samples in less than 90 seconds.

This collaboration is the beginning of a joint development program that will use multiplex bio-marker binding agents to analyse breath for 40 other diseases which include cancer, neurodegenerative, respiratory and metabolic conditions.
Dr Pete Hotten, CEO of PulmoBioMed, said: “PulmoBioMed is already recognised as best-in-class by analytical technology companies who are engaged in joint product development projects with the Company. Our focus is the development and commercialisation of breath sampling technology for integration with multiple partners analytical platforms in parallel with core healthcare applications.
“Future applications in the biosecurity and veterinary sectors will see PulmoBioMed seek to work with key partnerships in order to accelerate product development.”
Gerard Brandon CEO of DeepVerge plc, said: “When the scientific team at our York laboratories evaluated the breathalyser PBM-HALE™ device, we decided that there was greater opportunity to get a finished Covid-19 detection breathalyser system to the market faster by integrating the PulmoBioMed equipment into our Microtox Breath Test system. We are delighted to work with Dr Sterghios Moschos and his team and invest considerable resources in our joint development project and future collaboration on a range of real-time breath sample disease detection systems.”

PulmoBioMed - to develop world-leading medical device 16th March 2021

Scientists at Northumbria University have worked with the institution’s Research and Innovation Services to launch a medtech spinout company whose lead product for collecting breath samples could revolutionise diagnosis of a range of diseases, including Covid-19.

Northumbria’s Associate Professor Dr Sterghios Moschos, founder and PulmoBioMed’s Chief Scientific Officer, is supported by Chief Executive Officer Dr Pete Hotten, 20 years Board level management experience, Chief Operating Officer Jonathan Brookes, a Northumbria University alumnus with 15 years working in the medical device industry, and Chair, Dr Huw Edwards, with over 30 years of global experience in emerging diagnostic technologies.

Taking disruptive technology to market

The first of a series of products, PBM-Hale™ is a hand-held aerosol collecting device that allows sampling of the lung in a non-invasive way - by patients simply breathing into it.

To date, all products used for collecting breath samples have issues relating to contamination, sample loss and variability. The PBM-Hale™ technology resolves these issues, with devices currently being trialled in clinical centres across Europe.
Professor George Marston, Pro Vice-Chancellor (Research and Innovation) at Northumbria University, said: “This technology has the potential to deliver huge impact in healthcare on a global scale. We are a university ambitious to get our innovations out to the market to make a difference, and we encourage and support that process. This new business reflects the hard work of our entrepreneurial staff and the pioneering research we are doing at Northumbria University.”
The process of taking academic technology to create PulmoBioMed was made possible by support from Northern Accelerator, a collaboration between Northumbria, Durham, Newcastle and Sunderland Universities to commercialise research and boost the region’s economy.

Northern Accelerator’s ‘Proof-of-Concept’ funding supported the development of a first functional prototype. Northumbria graduate, Saqib Ali, was appointed as a Design Engineer at PulmoBioMed and carried out the rapid prototyping of PBM-HALE™ using 3D printers within the University’s engineering labs.

A second Northern Accelerator initiative, ‘Executives into Business’, supported the onboarding of the executive team, and a third programme of support, ‘Future Founders’, provided business training.

PulmoBioMed also benefitted from North by Northwest Partner’s ‘Innovation to the Commercialisation of University Research’ (ICURe) programme, which helped validate the market for the spinout’s technology. The company has additionally won funding from Innovate UK to support the first 18 months of business development activities.
PulmoBioMed is now seeking to close a £2.5m initial equity capital raise.

Hi Chesh,

And they are catching up with my holding too...

Surely it can't be long now before the market finally realises just what DVRG has got to offer now...tick tock

Mornin Chesh,

That 700k Whopper (gone large) surely a tasty buy?

Looks like our seller is still keeping it down (for now) so my Bed and ISA still looking safe.

ps If I was running NCYT I would buy up DVRG using their huge war chest of cash to be able to develop solutions worldwide for the future, frankly I am amazed that neither NCYT or AVCT have not made a bid for DVRG to date, it's a sitting duck at these prices but won't be for much longer I suspect.

Well I am hoping GB issues his big update at the end of the week or early next week...I have some Bed and ISA trades waiting to complete and they can take up to 5 working days to process!

If only we hadn't consolidated the shares 10:1, the SP could multi bag by itself without news judging by many AIM shares lately, seems like PIs just won't buy into shares valued at more than a penny or two....just joking but you know what I mean.

Nothing showing on Companies House as at 13:45 today

T.Rat, I think it's just a case of the market not working for us at the moment and being irrational. Just have to wait for it to catch up and remember, PIs will always buy into a rising share but hardly eve into a falling share or one that that is stuck in a small trading range. The herd is coming, just a question of when rather than if. Then you won't be able to get a post in amongst all the newbies and their questions and ramps....just saying how I see it. I was there in Skin plc back in the day when it went from 2.3p all the way back under 1p, seen it all before. Same with MWG that fell back a long way under 1p after a good rise. In Gerry we trust.

T.Rat Interesting:

The key features and potential benefits of MagnifEye to lateral flow test manufacturers and healthcare providers that use them are:
Improved accuracy of reading – avoiding human error and reading beyond the human visible spectrum to reduce the number of false negative test results
Fast response – provides lateral flow test results in under 2 seconds.?
Reduced risk of fraud – identifying tests that have been tampered with?
Automated provision of validated test results – securely linking to electronic health records
Faster generation of epidemiological insights – using Big Data analytics with the capacity to analyse the data across very large populations ?
Improved security – encrypted and securely held data transfer and storage with links to healthcare providers and public health officials?
Flexible – available in iOS, Android or web app formats, as an API or SDK (software development kit)